



Fox Rothschild LLP  
ATTORNEYS AT LAW

FEBRUARY 2012

INTELLECTUAL PROPERTY DEPARTMENT

# ALERT

## FDA ISSUES GUIDANCE ON BIOSIMILARS

By Gerard P. Norton, Ph.D., Esq. and Shahnám Sharareh, PharmD, RAC, Esq.

On Feb. 9, 2012, the U.S. Food and Drug Administration (FDA) issued three draft guidance documents on biosimilar product development in the United States. The guidance documents outline some of the scientific and quality issues with developing biosimilars, as well as industry questions about the implementation of the Biologics Price Competition and Innovation Act, part of the Patient Protection and Affordable Care Act.

The healthcare law created an approval pathway for biosimilars, or follow-on biologics, which are generic versions of protein-based products. The FDA said in the guidance documents that it expects biosimilars to be “highly similar” to the reference product, which is the original biological product that received approval.

Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, stated in a news release, “These draft documents are designed to help industry develop biosimilar versions of currently approved biological products, which can enhance competition and may lead to better patient access and lower cost to

consumers.”

As the cornerstone for demonstrating biosimilarity, the guidelines call for a stepwise approach to assess structural and functional characterization of both the proposed product and the reference product. Ultimately, based on the totality of evidence, no clinically meaningful difference should exist between the proposed and reference products. The FDA will seek public comment on the guidance documents during a 60-day comment period. Instructions on how to submit comments will be announced in an upcoming Federal Register notice.

Fox Rothschild will report on important developments as they occur. If you have questions about this Alert or would like information on becoming involved in the comment development process, please contact Gerard P. Norton at 609.844.3020 or [gnorton@foxrothschild.com](mailto:gnorton@foxrothschild.com) or Shahnám Sharareh at 609.844.3030 or [ssharareh@foxrothschild.com](mailto:ssharareh@foxrothschild.com) or any member of Fox Rothschild’s Intellectual Property Department.



Fox Rothschild LLP  
ATTORNEYS AT LAW

Attorney Advertisement

© 2012 Fox Rothschild LLP. All rights reserved. All content of this publication is the property and copyright of Fox Rothschild LLP and may not be reproduced in any format without prior express permission. Contact [marketing@foxrothschild.com](mailto:marketing@foxrothschild.com) for more information or to seek permission to reproduce content. This publication is intended for general information purposes only. It does not constitute legal advice. The reader should consult with knowledgeable legal counsel to determine how applicable laws apply to specific facts and situations. This publication is based on the most current information at the time it was written. Since it is possible that the laws or other circumstances may have changed since publication, please call us to discuss any action you may be considering as a result of reading this publication.